These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Mortalin/GRP75 binds to complement C9 and plays a role in resistance to complement-dependent cytotoxicity. Saar Ray M, Moskovich O, Iosefson O, Fishelson Z. J Biol Chem; 2014 May 23; 289(21):15014-22. PubMed ID: 24719326 [Abstract] [Full Text] [Related]
3. Mortalin inhibitors sensitize K562 leukemia cells to complement-dependent cytotoxicity. Pilzer D, Saar M, Koya K, Fishelson Z. Int J Cancer; 2010 Mar 15; 126(6):1428-35. PubMed ID: 19739077 [Abstract] [Full Text] [Related]
4. Complement membrane attack complex, perforin, and bacterial exotoxins induce in K562 cells calcium-dependent cross-protection from lysis. Reiter Y, Ciobotariu A, Jones J, Morgan BP, Fishelson Z. J Immunol; 1995 Aug 15; 155(4):2203-10. PubMed ID: 7636268 [Abstract] [Full Text] [Related]
5. Cooperation between Hsp90 and mortalin/GRP75 in resistance to cell death induced by complement C5b-9. Rozenberg P, Ziporen L, Gancz D, Saar-Ray M, Fishelson Z. Cell Death Dis; 2018 Feb 02; 9(2):150. PubMed ID: 29396434 [Abstract] [Full Text] [Related]
6. Emission of membrane vesicles: roles in complement resistance, immunity and cancer. Pilzer D, Gasser O, Moskovich O, Schifferli JA, Fishelson Z. Springer Semin Immunopathol; 2005 Nov 02; 27(3):375-87. PubMed ID: 16189651 [Abstract] [Full Text] [Related]
7. Complement triggers relocation of Mortalin/GRP75 from mitochondria to the plasma membrane. Mazkereth N, Rocca F, Schubert JR, Geisler C, Hillman Y, Egner A, Fishelson Z. Immunobiology; 2016 Dec 02; 221(12):1395-1406. PubMed ID: 27475989 [Abstract] [Full Text] [Related]
8. Incorporation of human complement C8 into the membrane attack complex is mediated by a binding site located within the C8beta MACPF domain. Brannen CL, Sodetz JM. Mol Immunol; 2007 Feb 02; 44(5):960-5. PubMed ID: 16624411 [Abstract] [Full Text] [Related]
9. Monoclonal antibodies directed against human C5 and C8 block complement-mediated damage of xenogeneic cells and organs. Rollins SA, Matis LA, Springhorn JP, Setter E, Wolff DW. Transplantation; 1995 Dec 15; 60(11):1284-92. PubMed ID: 8525523 [Abstract] [Full Text] [Related]
16. Involvement of the c-jun N-terminal kinases JNK1 and JNK2 in complement-mediated cell death. Gancz D, Donin N, Fishelson Z. Mol Immunol; 2009 Dec 15; 47(2-3):310-7. PubMed ID: 19864026 [Abstract] [Full Text] [Related]
18. Sublytic complement attack protects tumor cells from lytic doses of antibody and complement. Reiter Y, Ciobotariu A, Fishelson Z. Eur J Immunol; 1992 May 15; 22(5):1207-13. PubMed ID: 1577063 [Abstract] [Full Text] [Related]
19. Extracellular phosphorylation of C9 by protein kinase CK2 regulates complement-mediated lysis. Bohana-Kashtan O, Pinna LA, Fishelson Z. Eur J Immunol; 2005 Jun 15; 35(6):1939-48. PubMed ID: 15902683 [Abstract] [Full Text] [Related]
20. Paroxysmal nocturnal hemoglobinuria type III. Lack of an erythrocyte membrane protein restricting the lysis by C5b-9. Hänsch GM, Schönermark S, Roelcke D. J Clin Invest; 1987 Jul 15; 80(1):7-12. PubMed ID: 3597779 [Abstract] [Full Text] [Related] Page: [Next] [New Search]